BUPROPION AS A MODULATOR OF DRUG ACTIVITY
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
1 . A dosage form comprising:
about 105 mg of bupropion hydrochloride, or a molar equivalent amount of a bupropion in a free base or another salt form; and
about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of a dextromethorphan in a free base or another salt form.
2 . The dosage form of claim 1 , comprising about 105 mg of bupropion hydrochloride and about 45 mg of dextromethorphan hydrobromide.
3 . The dosage form of claim 1 , wherein the dextromethorphan is formulated for immediate release.
4 . The dosage form of claim 1 , wherein the bupropion is formulated for sustained release.
5 . A method of systemically delivering the bupropion and the dextromethorphan, comprising administering the dosage form of claim 1 to a human being.
6 . The method of claim 5 , wherein the dosage form is administered orally.
7 . The method of claim 5 , wherein the dosage form is administered once daily.
8 . The method of claim 5 , wherein the dosage form is administered twice daily.
9 . The method of claim 5 , wherein the dosage form is administered for at least 8 consecutive days.
10 . The method of claim 5 , wherein the dosage form is administered for at least 14 consecutive days.
11 . The method of claim 5 , wherein the dosage form is administered for at least 30 consecutive days.
12 . A dosage form comprising:
about 210 mg of bupropion hydrochloride, or a molar equivalent amount of a bupropion in a free base or another salt form; and
about 90 mg of dextromethorphan hydrobromide, or a molar equivalent amount of a dextromethorphan in a free base or another salt form.
13 . The dosage form of claim 12 , comprising about 210 mg of bupropion hydrochloride and about 90 mg of dextromethorphan hydrobromide.
14 . The dosage form of claim 12 , wherein the dextromethorphan is formulated for immediate release.
15 . The dosage form of claim 12 , wherein the bupropion is formulated for sustained release.
16 . A method of systemically delivering the bupropion and the dextromethorphan, comprising administering the dosage form of claim 12 to a human being.
17 . The method of claim 16 , wherein the dosage form is administered orally.
18 . The method of claim 16 , wherein the dosage form is administered once daily.
19 . The method of claim 16 , wherein the dosage form is administered for at least 8 consecutive days.
20 . The method of claim 16 , wherein the dosage form is administered for at least 14 consecutive days.
21 . The method of claim 16 , wherein the dosage form is administered for at least 30 consecutive days.